|
|
|
|
|
Ifosfamide
drug data and news
Ifosfamide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Ifosfamide | ||
| Brand Names/Synonyms | A 4942; Asta Z 4942; Cyfos; Holoxan 1000; I-Phosphamide; IFEX; Ifex; Ifex/Mesnex Kit; Ifosfamid; Ifosfamide; Ifosfamide Sterile; Ifosfamide/Mesna Kit; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; MJF 9325; Mitoxana; Naxamide; Z 4942 | ||
| Indication | For third line chemotherapy of germ cell testicular cancer. It should ordinarily be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Ifosfamide selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Ifosfamide-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. | ||
| Mechanism Of Action | After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily due to cross-linking of strands of DNA and RNA, as well as inhibition of protein synthesis. | ||
| Ifosfamide News (When available) |
NCCN Announces Important Updates to Ovarian Cancer Clinical ... 07 Mar 2006 ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone ... Feb 21, 2006 ZIOPHARM Treats First Patient in ZIO-201 Phase I/II in Sarcoma ... Feb 23, 2006 ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone ... Feb 21, 2006 Ziopharm initiates trial of sarcoma drug Feb 24, 2006 Neoadjuvant Sarcoma Chemotherapy Results in High Toxicity Levels Mar 1, 2006 Ziopharm compound shows potential for bone marrow transplants Feb 21, 2006 Neoadjuvant Chemotherapy and Radiotherapy Promising for Large Soft ... Mar 3, 2006 ZIOPHARM Presents ZIO-201 Preclinical Data at Bone Marrow ... Feb 17, 2006 ARIAD Initiates First Clinical Trial of Oral AP23573 in ... Feb 14, 2006 FDA Approves EMEND(R) (aprepitant), in Combination with Other ... Jan 11, 2006 Novel Strategies for Treating Lung Cancer: Chemotherapy Jan 24, 2006 Cisplatin Benefits Patients with Metastatic Osteosarcoma Jan 12, 2006 ZIOPHARM Oncology Announces ZIO-201 ASH Abstract Publication Nov 21, 2005 Survival rate still poor when bone cancer returns Dec 2, 2005 Despite Poor Prognosis, New Treatment Options for Mesothelioma May ... Nov 15, 2005 Ifosfamide/Paclitaxel/Cisplatin Highly Effective for Recurrent ... Sep 22, 2005 Taxol®, Ifex® and Platinol® Effective Second-Line Therapy for ... Sep 22, 2005 ZIOPHARM, Inc. and EasyWeb, Inc. Merge to Form ZIOPHARM Oncology ... Sep 15, 2005 Chemotherapy and Stem Cells Combat Osteosarcoma Sep 20, 2005 Tandem High-dose Treatments Better than Single High-dose Treatment ... Aug 2, 2005 New Regimen Effective for Relapsed Non-Hodgkin’s Lymphoma Jul 18, 2005 Palliative Pain Management: When Both Pain and Suffering Hurt Jul 15, 2005 New Regimen Effective For Refractory non-Hodgkin's Lymphoma Jun 3, 2005 ZIOPHARM Presents ZIO-201 Preclinical Data at AACR; Phase I ... Apr 19, 2005 News For Your Web Site Apr 19, 2005 ZIOPHARM Announces Approval of IND for ZIO-101; Phase I Trial in ... Apr 5, 2005 Baxa Sponsors Exhibitor’s Theatre on Reducing Environmental Apr 6, 2005 Powerful drugs endanger unprotected health workers Mar 10, 2005 Brain tumor with dismal prognosis in infants can be cured in older ... Mar 2, 2005 What if the Cure is Also a Cause? Feb 14, 2005 | ||
| Dosage Forms | Powder for solution | ||
| Drug_Category | Antineoplastic Agents; Immunosuppressive Agents; ATC:L01AA06 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Ifosfamide: The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs, including other cytotoxic drugs. | ||
| Toxicity | LD50 (mouse) = 390-1005 mg/kg, LD50 (rat) = 150-190 mg/kg. Side effects include nausea, vomiting and myelosuppression. Toxic effects include central nervous system toxicity (confusion, hallucinations) and urotoxic effects (cystitis, blood in urine). | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N,3-bis(2-chloroethyl)-2-oxo-1-oxa-3-aza-2$l^{5}-phosphacyclohexan-2-amine | ||
| Chemical Formula | C7H15Cl2N2O2P | ||
| Molecular Weight | 261.085 g/mol | ||
| Smiles String | C1CN(P(=O)(OC1)NCCCl)CCCl | ||
| Melting Point | 39-41 °C | ||
| Water Solubility | 3780 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 0.86 (exp) | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily hepatic | ||
| Half Life | 7-15 hours | ||
| Protein Binding [%] | Minimal | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Ifosfamide.html http://www.rxlist.com/cgi/generic2/ifosfamide.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00007 | ||
| CAS Registry Number | 3778-73-2 | ||
| KEGG Compound ID | C07047 | ||
| PubChem ID | SID:162510 | ||
| PharmGKB ID | PA449964 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2246565 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |